Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus

Ball, EM; Gibson, David; Bell, Andrew S.; Rooney,

doi:10.1177/0961203313512882

Cited by 63 publications

(45 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Interestingly, Ball et al described association of serum IL-6 with arthritis on physical examination and pD score in patients with systemic lupus erythematosus [27]. Overall, these findings [26,27] may result from a prominent synovial production of IL-6. In fact, IL-6 stimulates angiogenesis [28], and this could eventually explain the association of IL-6 concentrations with a positive pD in RA.…”

Section: Ultrassound Parameters and Synovial Tissuementioning

confidence: 97%

Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?

et al. 2018

View full text Add to dashboard Cite

High-resolution musculoskeletal ultrasound (MSUS) has been increasingly employed in daily rheumatological practice and in clinical research. In rheumatoid arthritis (RA), MSUS can be now considered a complement to physical examination. This method evaluates synovitis through gray-scale and power Doppler and it is also able to identify bone erosions. The utilization of MSUS as a marker of RA activity has received attention in recent literature. Current data account for good correlation of MSUS with classical measures of clinical activity; in some instances, MSUS appears to perform even better. Diagnosis of subclinical synovitis by MSUS might help the physician in RA management. With some variation, interobserver MSUS agreement seems excellent for erosion and good for synovitis. However, lack of MSUS score standardization is still an unmet need. In this review, we describe several MSUS scores, as well as their correlation with clinical RA activity and response to therapy. Finally, we look at the relationship of MSUS with synovial tissue inflammation and discuss future perspectives for a better interpretation and integration of this imaging method into clinical practice.

show abstract

Section: Ultrassound Parameters and Synovial Tissuementioning

confidence: 97%

Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…IL-6 is a pleiotropic cytokine strongly implicated in particular in lupus nephritis [26,27] and arthritis [28]. It shares several activities with IL-1 and tumor necrosis factor alpha, which have also been implicated in SLE, in the induction of pyrexia and the production of acute phase proteins.…”

Section: Dehydroeipandrosteronementioning

confidence: 99%

Immunomodulators in SLE: Clinical evidence and immunologic actions

Durcan

Petri

2016

Journal of Autoimmunity

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a potentially fatal autoimmune disease. Current treatment strategies rely heavily on corticosteroids, which are in turn responsible for a significant burden of morbidity, and immunosuppressives which are limited by suboptimal efficacy, increased infections and malignancies. There are significant deficiencies in our immunosuppressive armamentarium, making immunomodulatory therapies crucial, offering the opportunity to prevent disease flare and the subsequent accrual of damage. Currently available immunomodulators include prasterone (synthetic dehydroeipandrosterone), vitamin D, hydroxychloroquine and belimumab. These therapies, acting via numerous cellular and cytokine pathways, have been shown to modify the aberrant immune responses associated with SLE without overt immunosuppression. Vitamin D is important in SLE and supplementation appears to have a positive impact on disease activity particularly proteinuria. Belimumab has specific immunomodulatory properties and is an effective therapy in those with specific serological and clinical characteristics predictive of response. Hydroxychloroquine is a crucial background medication in SLE with actions in many molecular pathways. It has disease specific effects in reducing flare, treating cutaneous disease and inflammatory arthralgias in addition to other effects such as reduced thrombosis, increased longevity, improved lipids, better glycemic control and blood pressure. Dehydroeipandrosterone is also an immunomodulator in SLE which can have positive effects on disease activity and has bone protective properties. This review outlines the immunologic actions of these drugs and the clinical evidence supporting their use.

show abstract

“…It has been identified in kidney biopsy tissue from patients with SLE with active glomerulonephritis (36). Skin biopsies from patients with SLE have exhibited increased expression of IL‐6 in active sites (37), and plasma levels of IL‐6 have correlated with lupus arthritis (38). In addition, higher levels of IL‐6 in synovial fluid increase the risk of joint destruction in patients with RA (39).…”

Section: Synthetic Cannabinoidsmentioning

confidence: 99%

Cannabinoids, inflammation, and fibrosis

Zurier

Burstein

2016

FASEB j.

View full text Add to dashboard Cite

Cannabinoids apparently act on inflammation through mechanisms different from those of agents such as nonsteroidal anti-inflammatory drugs (NSAIDs). As a class, the cannabinoids are generally free from the adverse effects associated with NSAIDs. Their clinical development thus provides a new approach to treatment of diseases characterized by acute and chronic inflammation and fibrosis. A concise survey of the anti-inflammatory actions of the phytocannabinoids Δ-tetrahydrocannabinol (THC), cannabidiol, cannabichromene, and cannabinol is presented. Mention is also made of the noncannabinoid plant components and pyrolysis products, followed by a discussion of 3 synthetic preparations-Cesamet (nabilone; Meda Pharmaceuticals, Somerset, NJ, USA), Marinol (dronabinol; THC; AbbVie, Inc., North Chicago, IL, USA), and Sativex (Cannabis extract; GW Pharmaceuticals, Cambridge United Kingdom)-that have anti-inflammatory effects. A fourth synthetic cannabinoid, ajulemic acid (AJA; CT-3; Resunab; Corbus Pharmaceuticals, Norwood, MA, USA), is discussed in greater detail because it represents the most recent advance in this area and is currently undergoing 3 phase 2 clinical trials by Corbus Pharmaceuticals. The endogenous cannabinoids, including the closely related lipoamino acids, are then discussed. The review concludes with a presentation of a possible mechanism for the anti-inflammatory and antifibrotic actions of these substances. Thus, several cannabinoids may be considered candidates for development as anti-inflammatory and antifibrotic agents. Of special interest is their possible use for treatment of chronic inflammation, a major unmet medical need.-Zurier, R. B., Burstein, S. H. Cannabinoids, inflammation, and fibrosis.

show abstract

Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus

Abstract: This is the first study to examine levels of specific cytokines in a cohort of SLE patients stratified in terms of joint disease by US, where the most significant finding is that IL-6 levels correlated both with clinical and US measures of arthritis disease activity.

Cited by 63 publications

References 46 publications

Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?

Ultrasound and its clinical use in rheumatoid arthritis: where do we stand?

Immunomodulators in SLE: Clinical evidence and immunologic actions

Cannabinoids, inflammation, and fibrosis

Contact Info

Product

Resources

About